Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental FatigueBusiness Wire • 9 days ago
Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced...
Share to Feed
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological...
VTGN's total volume now sits at 921.6K. The +2.10% price change was insignificant, leaving IBM's price at $5.39...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological...
Key Insights The considerable ownership by individual investors in Vistagen Therapeutics indicates that they...
This is a signal that VTGN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
This price move could indicate a change in the trend, and may be a buy signal for investors...
This price move could be a signal that VTGN may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...
This indicator may be signaling VTGN's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
For the last three days, A.I.dvisor has detected that VTGN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...